Drug
CEP-9722 clinical trials
Also written CEP-9722.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How studies write it
Studies that test it under each name
Development codes
- CEP-9722
- 3
Studies by the year they started
3 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Cephalon (2) · Teva Branded Pharmaceutical Products R&D, Inc. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses CEP-9722 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid TumorsTerminatedPhase 1/2Teva Branded Pharmaceutical Products R&D, Inc.NCT01311713Written as CEP-9722
- Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell LymphomaCompletedPhase 1CephalonNCT01345357Written as CEP-9722
- Study of CEP-9722 as Single-Agent Therapy and as Combination Therapy With Temozolomide in Patients With Advanced Solid TumorsCompletedPhase 1CephalonNCT00920595Written as CEP-9722
Codes
What other systems call CEP-9722 · ClinicalTrials.gg INT000220
- UNII (FDA) B68083E4YGCEP-9722One source FDA
- NCI Thesaurus C84880PARP Inhibitor CEP-9722One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | B68083E4YG | CEP-9722 | One source FDA |
| NCI Thesaurus | C84880 | PARP Inhibitor CEP-9722 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.